SUMMARY Seven paediatric patients with central diabetes insipidus were studied in an open dose ranging study in hospital followed by a six month study on an outpatient basis to assess the efficacy and safety of peroral administration of DDAVP (desmopressin) tablets. In the dose ranging study a dose dependent antidiuretic response was observed. The response to 12-5-50 mcg was, however, less effective in correcting baseline polyuria than were doses of 100 mcg and above. Patients were discharged from hospital on a preliminary dosage regimen ranging from 100 to 400 mcg three times daily. After an initial adjustment in dosage in three patients at one week follow up, all patients were stabilised on treatment with tablets and reported an adequate water turnover at six months. As with the intranasal route of administration dosage requirements varied from patient to patient, and a dose range rather than standard doses were required. A significant correlation, however, was found for the relation between previous intranasal and present oral daily dosage.
Diabetes insipidus in children is a rare disease caused by a deficiency of the antidiuretic hormone, vasopressin. This deficiency leads to a failure to conserve water and results in a polyuria and compensatory polydipsia. Due to the inability to concentrate urine, the child with untreated diabetes insipidus will have high urinary losses, and if treatment is not begun promptly there is a danger of rapid dehydration. If the disease is untreated or badly controlled the child can develop chronic dehydration, unexplained fever, vomiting, constipaion, and failure to thrive. These may lead to serious neurological disturbances not always corrected when substitution treatment is started.
The aetiology of diabetes insipidus is most often a destructive process along the hypothalamopituitary axis. In childhood the cause of this damage is often a tumour -that is, craniopharyngioma. Consequently, diabetes insipidus will often develop in a child operated on for a pituitary tumour or one located near the pituitary. ' In addition, many of these children have other pituitary dysfunctions and also impairment of vision due to lesions of the optic tracts.
Diabetes insipidus was earlier treated with vasopressin and its analogues such as lysine vasopressin or mixtures of lysine and arginine vasopressin. These drugs, however, produce several side effects, partly due to their pressor activity. 12 These facts led to a study in adult patients where it was described that a daily oral dosage of 100-200 mcg three times daily was sufficient to control polyuria.'3 Against this background, we designed a study to evaluate the efficacy and safety of oral desmopressin in paediatric patients and to obtain information on the correlation between intranasal and oral dosing.
Materials and methods
Patients. Seven patients (six boys and one girl) with central diabetes insipidus were studied. Ages ranged from 4 to 18 years (mean 12 6 years). All had diabetes insipidus secondary to tumours, and six had been operated on for a craniopharyngioma and one for a pituitary adenoma. The diagnosis of diabetes insipidus had previously been confirmed by a standard water deprivation test. Patients were being treated with standard daily doses of intranasal desmopressin ranging from 5-60 mcg (mean 25 mcg). In addition, all patients were receiving concomitant treatment with drugs for other pituitary deficiencies, including thyroxine, cortisone acetate, and growth hormone. Three patients had impaired vision secondary to the tumour or the treatment of the tumour. After thorough information about the study had been given, written informed consent was obtained from parents. The study protocol was approved by the hospital's ethics committee. duration and magnitude of response is seen for each rising dose. For each patient an individual dose response analysis was performed by calculating the maximum urine osmolality after each dose ( Figure  2 ). A significant correlation was observed between log maximum urine osmolality and log desmopressin dose by body weight (r=0-61, p<005). The response to 100 mcg doses and above gave rise to a more concentrated urine osmolality, and most patients could be discharged from hospital with an initial dosage regimen of 100-200 mcg desmopressin three times daily. An exception was case 3, a 15 year old male, body weight 95 kg, who was started on 400 mcg desmopressin three times daily.
No adverse reactions to the administration of desmopressin at any dose level were observed. No clinically significant changes were noted in body weight, blood pressure, or heart rate. three patients, after which all were stabilised on treatment at six months follow up. During this period daily diuresis was similar to diuresis during the period on intranasal treatment. The mean daily dosage was 550 mcg (range: 100 mcg twice daily to 400 mcg three times daily). In comparison, the previous mean intranasal dosage had been 25 mcg (range: 5 mcg nightly to 20 mcg three times daily). Figure 3 shows a linear correlation between previous daily intranasal doses and current daily tablet doses (r=0-79, p<0-05). At six month follow up no clinically significant changes in laboratory safety variables were recorded and no adverse reactions were observed.
Discussion
Since its introduction desmopressin has been the drug of choice in the treatment of diabetes insipidus, although the mode of administration, intranasally with a tube, has several practical disadvantages. between patients, a linear correlation was observed between dose and urine osmolality. A similar correlation was reported by Moses et al after desmopressin had been administered subcutaneously in doses of 0*5-4-0 mcg whereby doubling the dose lengthened its action by four hours. '4 In this study, a mean antidiuretic activity of eight hours was achieved at doses of 100-400 mcg. The patients showed a great interindividual variation both in magnitude and duration of response, but the dose range was found to be of the same order as for intranasal desmopressin, which had previously been administered in daily doses of 5-60 mcg. The aetiology of this wide range is probably due to the variation in secretion of endogenous vasopressin.
As with the intranasal route of administration individual dosage requirements will vary, and a standard dose schedule is not possible. A significant correlation was found, however, between the intranasal and the oral dose indicating a ratio of 1:20. A suitable oral dose for most patients will probably be in the range of 100-400 mcg three times daily. Some of our patients switched from twice daily intranasal administration to three times daily oral administration. In our experience, however, the children did not find this to be a serious drawback.
Compared with the peroral dose used by Vilhardt et al,'3 our daily dose is higher. This could possibly be explained by different kinetics between adults and children or by differences in patient selection. It is most likely, however, to be due to more practical aspects, such as the higher water turnover in adults, whereby higher fluid losses are compensated by extra water intake (Hammer, personal communication) . Moreover, as children need more sleep at night than adults a larger dose at bedtime was given to minimise night time diuresis and ensure adequate duration of sleep.
It should be emphasised that it is important to follow the patient's urinary output closely, especially during changes in treatment. One reason for this is that the children and parents in our experience have a tendency to underestimate the child's urinary output, which implies that many patients may be undertreated.
This study shows that treatment with desmopressin tablets is effective and safe for diabetes insipidus in children. All children expressed a preference for the tablets. The doses needed to control polyuria are higher than with intranasal administration, but this is outweighed by the numerous advantages of the tablet form. Our patients have now been on continuous treatment with tablets for 10 months. To date, we have not observed any loss of efficacy or side effects. diabetes insipidus. 
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